Shire launches ADHD med Mydayis as it weighs a neuroscience exit by Eric Sagonowsky Monday, August 28, 2017 Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.
Shire hints at ADHD spinoff, but could someone buy the neuro group? by Arlene Weintraub Thursday, August 3, 2017 Shire's neuroscience unit, anchored by drugs to treat ADHD, may be on the block.
Shire scores FDA nod for Mydayis, its latest Adderall iteration by Tracy Staton Wednesday, June 21, 2017 Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
